With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.101691-65-0,(Tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate,as a common compound, the synthetic route is as follows.
To a solution of Example 95A (9.1 g, 33.7 mmol) in EtOH (50 mL) was added hydrazine hydrate (3.3 mL, 67.3 mmol). The mixture was warmed to reflux (85 C.) and was allowed to stir for 20 hours. The mixture was cooled to ambient temperature then 4,4-dimethyl-3-oxopentanenitrile (8.4 g, 67.3 mmol) was added and the mixture was again warmed to reflux (85 C.) and was allowed to stir for 6 hours. The mixture was concentrated under reduced pressure and the residue was dissolved in CH2Cl2 (30 mL) and saturated aqueous NaHCO3 (20 mL) was added slowly. The layers were separated and the aqueous phase was extracted with CH2Cl2 (3¡Á10 mL). The combined organic extracts were dried over Na2SO4, filtered and concentrated under reduced pressure. Purification via column chromatography (SiO2, 50% hexanes/EtOAc to 100% EtOAc to 9:1:0.1 EtOAc:MeOH:Et3N) provided the title compound (5.2 g, 21.9 mmol, 65% yield). MS (DCI/NH3) m/z 238 (M+H)+, 101691-65-0
Big data shows that 101691-65-0 is playing an increasingly important role.
Reference£º
Patent; ABBOTT LABORATORIES; US2010/69348; (2010); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics